Immunotherapy cocktail takes on deadly thyroid cancer
NCT ID NCT03181100
First seen Jun 25, 2026 · Last updated Jul 24, 2026 · Updated 4 times
Summary
This phase 2 trial tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy can help people with anaplastic or poorly differentiated thyroid cancer live longer. About 50 patients with advanced or inoperable cancer are receiving different drug combinations. The study is active but no longer recruiting new participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Atezolizumab (immunotherapy) plus chemotherapy drugs (bevacizumab, vemurafenib, cobimetinib, nab-paclitaxel, paclitaxel)
- What this could lead to
- If successful, this could offer a new treatment option for aggressive thyroid cancers that are hard to treat.
- What could go wrong
- This is a small, early-phase trial (50 people) with no results yet. The combination may not work better than standard treatments and could have serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC THYROID GLAND CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New hope for rare, aggressive thyroid cancer: drug combo shows promise
- New radioactive drug targets Hard-to-Treat cancers in early trial
- Could your own tumor cells fight cancer? new trial tests immune cell therapy
- New drug combo offers hope for hard-to-treat thyroid cancer
- New combo therapy takes on deadly thyroid cancer in early trial
- New drug combo targets Hard-to-Treat thyroid cancer